Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Hodgkin Lymphoma
•
Hematology
Is there a role at this time for chemo-immunotherapy in the upfront treatment of classic Hodgkin lymphoma?
Although not approved, for example, are you every using AVD-nivolumab?
Related Questions
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?
Is your standard of care for newly diagnosed advanced classical Hodgkin now nivolumab-AVD based on SWOG 1826?
How do you decide between treatment with ABVD vs A + AVD in a patient in their 70s with advanced stage 4 classical Hodgkin lymphoma?
How you treat large B-cell lymphoma with IRF4 rearrangement?
What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?
Have you utilized a dose-reduced approach for elderly patients receiving frontline Pola-R-CHP similar to R-miniCHOP?
How would you manage a patient with symptomatic low grade leukemic NHL w/o a clear diagnosis of either FL or MZL?
What is your treatment approach for HIV-associated large B-cell lymphoma (DLBCL) with secondary CNS involvement?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?